Patents by Inventor Frédéric Jaisser

Frédéric Jaisser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF NGAL PROTEIN
    Publication number: 20220054493
    Abstract: This invention relates to compounds that are inhibitors of NGAL activity, and applications thereof.
    Type: Application
    Filed: March 6, 2020
    Publication date: February 24, 2022
    Inventors: Frédéric JAISSER, Ernesto MARTINEZ-MARTINEZ, Paul MULDER, Antoine OUVRARD-PASCAUD, Philippe BERNARD, Quoc Tuan DO
  • Methods for the treatment of cardiovascular fibrosis
    Patent number: 10167468
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of cardiovascular fibrosis. In particular, the present invention relates to an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) activity or expression for use in a method for treating or preventing cardiovascular fibrosis in a subject in need thereof.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: January 1, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE LORRAINE, CENTRE HOSPITALIER ET UNIVERSITAIRE DE NANCY (CHU), UNIVERSITE PARIS DIDEROT-PARIS 7, UNIVERSITE PARIS DESCARTES
    Inventors: Frederic Jaisser, Nicolette Farman, Antoine Tarjus, Patrick Rossignol, Faiez Zannad
  • Pharmaceutical compositions for preventing glucocorticoid-induced corneal thinning
    Patent number: 10159684
    Abstract: The present invention relates to method and pharmaceutical compositions for preventing glucocorticoid-induced corneal or skin thinning. In particular, the present invention relates to a mineralocorticoid receptor antagonist for topical use in a method for preventing or reducing glucocorticoid-induced corneal or skin thinning in a subject in need thereof. The invention also relates to a topical pharmaceutical composition comprising an amount of at least one glucocorticoid and an amount of at least one mineralocorticoid receptor antagonist or inhibitor of MR expression for use in a method for treating an inflammatory skin disease or an inflammatory disease of the cornea or of the anterior segment of the eye in a subject in need thereof.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: December 25, 2018
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DESCARTES, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP)
    Inventors: Nicolette Farman, Frederic Jaisser, Francine Behar-Cohen, Selin Aractingi, Van Tuan Nguyen
  • Method for treatment of heart failure
    Patent number: 10059946
    Abstract: The present invention relates to an inhibitor of NGAL gene expression or a NGAL antagonist for use in the prevention or the treatment of heart failure.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: August 28, 2018
    Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Frédéric Jaisser, Nicolette Farman
  • Biomarkers of mineralocorticoid receptor activation
    Patent number: 10041122
    Abstract: The present invention relates to the use of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and/or SERPINA3 as biomarkers of the Mineralocorticoid Receptor (MR) activation in a patient. More particularly, the present invention relates to a method for predicting the responsiveness of a patient to a treatment with a MR antagonist or an aldosterone synthase inhibitor, said method comprising determining in a biological sample obtained from said patient the expression level of the NGAL gene and/or of the SERPINA3 gene.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: August 7, 2018
    Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Frederic Jaisser, Nicolette Farman, Yannis Sainte-Marie, Celine Latouche, Marja Steenman
  • PHARMACEUTICAL COMPOSITIONS FOR PREVENTING GLUCOCORTICOID-INDUCED CORNEAL OR SKIN THINNING
    Publication number: 20170273992
    Abstract: The present invention relates to method and pharmaceutical compositions for preventing glucocorticoid-induced corneal or skin thinning. In particular, the present invention relates to a mineralocorticoid receptor antagonist for topical use in a method for preventing or reducing glucocorticoid-induced corneal or skin thinning in a subject in need thereof. The invention also relates to a topical pharmaceutical composition comprising an amount of at least one glucocorticoid and an amount of at least one mineralocorticoid receptor antagonist or inhibitor of MR expression for use in a method for treating an inflammatory skin disease or an inflammatory disease of the cornea or of the anterior segment of the eye in a subject in need thereof.
    Type: Application
    Filed: June 8, 2017
    Publication date: September 28, 2017
    Inventors: Nicolette FARMAN, Frederic JAISSER, Francine BEHAR-COHEN, Selin ARACTINGI, Van Tuan NGUYEN
  • Pharmaceutical compositions for preventing glucocorticoid-induced skin thinning
    Patent number: 9730948
    Abstract: The present invention relates to method and pharmaceutical compositions for preventing glucocorticoid-induced corneal or skin thinning. In particular, the present invention relates to a mineralocorticoid receptor antagonist for topical use in a method for preventing or reducing glucocorticoid-induced corneal or skin thinning in a subject in need thereof. The invention also relates to a topical pharmaceutical composition comprising an amount of at least one glucocorticoid and an amount of at least one mineralocorticoid receptor antagonist or inhibitor of MR expression for use in a method for treating an inflammatory skin disease or an inflammatory disease of the cornea or of the anterior segment of the eye in a subject in need thereof.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: August 15, 2017
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DESCARTES, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)
    Inventors: Nicolette Farman, Frederic Jaisser, Francine Behar-Cohen, Selin Aractingi, Van Tuan Nguyen
  • Methods and compositions for stimulating reepithelialisation during wound healing
    Patent number: 9682089
    Abstract: The present invention relates to methods and compositions for stimulating reepithelialization during wound healing. More particularly, the present invention relates to a mineralocorticoid receptor antagonist or an inhibitor of mineralocorticoid receptor gene expression for use in a method for stimulating reepithelialization of the skin or of the cornea during wound healing.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: June 20, 2017
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, UNIVERSITE PARIS DESCARTES
    Inventors: Nicolette Farman, Francine Behar-Cohen, Frederic Jaisser
  • Methods and Pharmaceutical Compositions for the Treatment of Cardiovascular Fibrosis
    Publication number: 20170166892
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of cardiovascular fibrosis. In particular, the present invention relates to an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) activity or expression for use in a method for treating or preventing cardiovascular fibrosis in a subject in need thereof.
    Type: Application
    Filed: January 31, 2017
    Publication date: June 15, 2017
    Inventors: Frederic Jaisser, Nicolette Farman, Antoine Tarjus, Patrick Rossignol, Faiez Zannad
  • Methods and compositions for the treatment of fluid accumulation in and/or under the retina
    Patent number: 9610294
    Abstract: The present invention provides methods and compositions for the treatment of fluid accumulation in and/or under the retina.
    Type: Grant
    Filed: January 2, 2015
    Date of Patent: April 4, 2017
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
    Inventors: Francine Behar-Cohen, Nicolette Farman, Frederic Jaisser
  • Method for the treatment of cardiovascular fibrosis
    Patent number: 9594083
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of cardiovascular fibrosis. In particular, the present invention relates to an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) activity or expression for use in a method for treating or preventing cardiovascular fibrosis in a subject in need thereof.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: March 14, 2017
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Lorraine, Cantre Hospitalier et Universitaire de Nancy (CHU), Universite Paris Diderot-Paris 7, Universite Paris Descartes
    Inventors: Frederic Jaisser, Nicolette Farman, Antoine Tarjus, Patrick Rossignol, Faiez Zannad
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEART FAILURE
    Publication number: 20170002358
    Abstract: The present invention relates to an inhibitor of NGAL gene expression or a NGAL antagonist for use in the prevention or the treatment of heart failure.
    Type: Application
    Filed: August 29, 2016
    Publication date: January 5, 2017
    Applicant: Institut National de la Sante et de la Recherche M edicale (INSERM)
    Inventors: Frédéric JAISSER, Nicolette FARMAN
  • Methods for the treatment of heart failure
    Patent number: 9533041
    Abstract: The present invention relates to an inhibitor of NGAL gene expression or a NGAL antagonist for use in the prevention or the treatment of heart failure.
    Type: Grant
    Filed: December 5, 2011
    Date of Patent: January 3, 2017
    Assignee: Institut National de la Santé et de la Recherche Médicale
    Inventor: Frédéric Jaisser
  • Biomarkers of Mineralocorticoid Receptor Activation
    Publication number: 20160362744
    Abstract: The present invention relates to the use of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and/or SERPINA3 as biomarkers of the Mineralocorticoid Receptor (MR) activation in a patient. More particularly, the present invention relates to a method for predicting the responsiveness of a patient to a treatment with a MR antagonist or an aldosterone synthase inhibitor, said method comprising determining in a biological sample obtained from said patient the expression level of the NGAL gene and/or of the SERPINA3 gene.
    Type: Application
    Filed: June 21, 2016
    Publication date: December 15, 2016
    Inventors: Frederic Jaisser, Nicolette Farman, Yannis Sainte-Marie, Celine Latouche, Marja Steenman
  • PHARMACEUTICAL COMPOSITIONS FOR PREVENTING GLUCOCORTICOID-INDUCED CORNEAL OR SKIN THINNING
    Publication number: 20160136183
    Abstract: The present invention relates to method and pharmaceutical compositions for preventing glucocorticoid-induced corneal or skin thinning. In particular, the present invention relates to a mineralocorticoid receptor antagonist for topical use in a method for preventing or reducing glucocorticoid-induced corneal or skin thinning in a subject in need thereof. The invention also relates to a topical pharmaceutical composition comprising an amount of at least one glucocorticoid and an amount of at least one mineralocorticoid receptor antagonist or inhibitor of MR expression for use in a method for treating an inflammatory skin disease or an inflammatory disease of the cornea or of the anterior segment of the eye in a subject in need thereof.
    Type: Application
    Filed: June 20, 2014
    Publication date: May 19, 2016
    Inventors: Nicolette FARMAN, Frederic JAISSER, Francine BEHAR-COHEN, Selin ARACTINGI, Van Tuan NGUYEN
  • METHODS AND COMPOSITIONS FOR STIMULATING REEPITHELIALISATION DURING WOUND HEALING
    Publication number: 20160082020
    Abstract: The present invention relates to methods and compositions for stimulating reepithelialisation during wound healing. More particularly, the present invention relates to a mineralocorticoid receptor antagonist or an inhibitor of mineralocorticoid receptor gene expression for use in a method for stimulating reepithelialisation of the skin or of the cornea during wound healing.
    Type: Application
    Filed: December 4, 2015
    Publication date: March 24, 2016
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, UNIVERSITE PARIS DESCARTES
    Inventors: Nicolette FARMAN, Francine BEHAR-COHEN, Frederic JAISSER
  • Methods and compositions for stimulating reepithelialisation during wound healing
    Patent number: 9241944
    Abstract: The present invention relates to methods and compositions for stimulating reepithelialization during wound healing. More particularly, the present invention relates to a mmeralocorticoid receptor antagonist or an inhibitor of mineralocorticoid receptor gene expression for use in a method for stimulating reepithelialization of the skin or of the cornea during wound healing.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: January 26, 2016
    Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique Hopitaux de Paris, Universite Paris Descartes
    Inventors: Nicolette Farman, Francine Behar-Cohen, Frédéric Jaisser
  • Methods and pharmaceutical compositions for the treatment of hypertension
    Patent number: 9212361
    Abstract: The present invention relates to an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) activity or expression for use in a method for treating or preventing hypertension in a subject in need thereof.
    Type: Grant
    Filed: April 18, 2013
    Date of Patent: December 15, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Diderot (Paris VII), Universite Paris Descartes
    Inventors: Frederic Jaisser, Nicolette Farman, Antoine Tarjus
  • Methods and Pharmaceutical Compositions for the Treatment of Cardiovascular Fibrosis
    Publication number: 20150247855
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of cardiovascular fibrosis. In particular, the present invention relates to an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) activity or expression for use in a method for treating or preventing cardiovascular fibrosis in a subject in need thereof.
    Type: Application
    Filed: September 27, 2013
    Publication date: September 3, 2015
    Inventors: Frederic Jaisser, Nicolette Farman, Antoine Tarjus, Patrick Rossignol, Faiez Zannad
  • Methods and kits for detecting cardiac remodeling in subjects without clinical signs of heart failure
    Patent number: 9121858
    Abstract: The present relates to a method for detecting cardiac remodeling in a subject without clinical signs of heart failure comprising determining the level of the NGAL-MMP9 complex in a blood sample obtained from the patient.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: September 1, 2015
    Assignees: Institute National de la Sante et de la Recherche Medicale (INSERM), Universite de Lorraine, Centre Hospaitalier et de Nancy (CHU), Universite Paris Descartes
    Inventors: Frederic Jaisser, Patrick Rossignol, Faiez Zannad